SV

Street Verdict

Analyst Scorecard

ANTHEM · NSE

Anthem Biosciences Limited

₹951.05

+1.52% (+₹14.25)

Prev. close

₹936.8

Volume

3,29,384

Delivery %

54.8%

As of

20 Nov 2026

Price history

₹951.05+₹60 (+6.73%) · 3M
18 Aug 2026 → 20 Nov 2026
85090095018 Aug09 Sept06 Oct29 Oct20 Nov
Daily closes · updates after each session

Analyst sentiment

No analyst stances in this range

0 analyst stances · last 90 days · one per analyst

Try a wider range.

Explore by date range →

Analyst opinions

CallAnalystInstrumentVerdictActions
Market commentary · 10 · levels, conditionals, previews, macro & hedged views — context, not graded
CallAnalystInstrumentVerdictActions

Fundamentals

About Anthem Biosciences Limited

Anthem Biosciences Limited operates as a contract research, development, and manufacturing organization in India, rest of Asia, North America, Europe, and internationally. It operates in two segments: Contract Manufacturing, Development & Discovery Services; and Speciality Ingredients. The company offers contract research development and manufacturing services, such as end-to-end services across the new chemical entity and new biological entity lifecycles, as well as engages in contract research, development, and manufacturing of development batches of molecules used for clinical trials up to commercial manufacturing for small molecules and biologics. It also manufactures and sells specialized fermentation-based active pharmaceutical ingredients, including probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars. The company was incorporated in 2006 and is based in Bengaluru, India.

Details

Sector

Healthcare

Industry

Biotechnology

CEO

Mr. Ajay Bhardwaj B.Tech., M.S

Headquarters

Bengaluru

Employees

2,282

Key stats

Market cap

₹50,058.20 Cr

P/E ratio (TTM)

87.5

Dividend yield

0.23%

EPS (TTM)

₹10.15

Beta (1Y · daily vs NIFTY 50)

0.51

Shares float

7.19 Cr

EPS · quarter ended Jun 2026

₹2.11

Financial Performance

01 · Financials

0 Cr1000 Cr2000 Cr3000 Cr₹0%10%20%30%40%FY21FY22FY23FY24FY25FY26
RevenueNet income ÷ revenue

Net income and EBITDA are omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures. Net income ÷ revenue is not drawn for FY21 and FY22 (no net income reported). Revenue for FY26: the figure the company printed, which its own totals confirm and the series' figure did not.

02 · Earnings Per Share (EPS)

051015₹FY23FY24FY25FY26

03 · Dividend Profile

01122₹0%0.1%0.2%0.3%25 Jun 26
Dividend (₹/share)Annualised yield

Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based

-100%-50%0%50%100%FY21FY22FY23FY24FY25FY26
SalesFixed assetsTrade receivablesInventory

05 · Capital Structure & Asset Utilization

0 Cr1000 Cr2000 Cr3000 Cr4000 Cr₹0×0.25×0.5×0.75×FY21FY22FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

0 Cr1000 Cr2000 Cr3000 Cr4000 Cr₹FY21FY22FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

-500 Cr0 Cr500 Cr1000 Cr₹FY21FY22FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

08 · Profit & Loss — as filed

Annual

Line itemFY25FY26
₹1,930.29 Cr₹2,280.12 Cr
I Revenue from operations
₹1,844.55 Cr₹2,124.33 Cr
II Other income
₹85.73 Cr₹155.78 Cr
₹656.87 Cr₹848.63 Cr
VI Exceptional items
—₹24.39 Cr
VII Profit/(Loss) before tax (V-VI)
₹656.87 Cr₹824.24 Cr
₹451.26 Cr₹591.79 Cr
₹450.86 Cr₹590.23 Cr
1) Basic EPS
8.0710.55
2) Diluted EPS
8.0410.43

The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.

All years: consolidated statements.

09 · Balance Sheet — as filed

Annual

Line itemFY25FY26
₹2,807.58 Cr₹3,429.29 Cr
₹1,319.41 Cr₹1,626.15 Cr
₹1,488.17 Cr₹1,803.15 Cr
₹2,807.58 Cr₹3,429.29 Cr
₹2,409.86 Cr₹3,042.52 Cr
₹71.49 Cr₹61.06 Cr
₹326.23 Cr₹325.71 Cr

The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.

All years: consolidated statements.

10 · Cash Flow Statement

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹278.00 Cr₹333.00 Cr₹306.00 Cr₹140.00 Cr₹271.00 Cr₹844.00 Cr
Investing cash flow
——₹-376.02 Cr₹-221.46 Cr₹-146.57 Cr₹-701.62 Cr
₹-63.00 Cr₹181.00 Cr₹64.00 Cr₹-77.00 Cr₹-136.00 Cr₹-40.00 Cr
Capital expenditure
₹-120.00 Cr₹-26.00 Cr₹-184.00 Cr₹-117.00 Cr₹-261.00 Cr₹-211.00 Cr
End cash position
——₹342.85 Cr₹184.36 Cr₹172.28 Cr₹274.88 Cr

Investing cash flow, Dividends paid, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source has no quarterly cash-flow-statement coverage.

11 · Shareholding Pattern

NSE, quarterly

Line itemJul 25–Dec 25(3Q)Mar 26Jun 26
Promoter74.69%74.68%71.42%
Public25.31%25.32%28.58%
Employee trusts0.00%0.00%0.00%

Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.25 L Cr₹1,769.938.85.0913.7%0.06+11.9%+3.7%
Divi's Laboratories Limited₹2.66 L Cr₹10,037.590.815.8515.3%0.00+12.3%+47.5%
Torrent Pharmaceuticals Limited₹1.79 L Cr₹4,738.579.421.3125.8%1.79+21.5%+32.5%
Laurus Labs Limited₹1.27 L Cr₹2,34894.823.9416.8%0.48+22.0%+146.2%
Apollo Hospitals Enterprise Limited₹1.23 L Cr₹8,599.558.812.9520.5%0.90+15.7%+10.1%
Zydus Lifesciences Limited₹1.19 L Cr₹1,188.126.74.4018.6%0.46+18.4%+22.3%
Lenskart Solutions Limited₹1.16 L Cr₹689.7181.413.305.6%0.35+35.4%—
Dr. Reddy's Laboratories Limited₹1.14 L Cr₹1,37440.63.0211.4%0.21+3.2%+14.5%
Cipla Limited₹1.13 L Cr₹1,40238.93.2711.3%0.02+2.1%-6.7%
Mankind Pharma Limited₹1.03 L Cr₹2,47545.96.3111.7%0.39+17.0%+3.1%
Aurobindo Pharma Limited₹98,101.93 Cr₹1,70526.62.599.2%0.21+6.4%+48.4%
Anthem Biosciences Limited₹48,150.66 Cr₹888.384.215.8319.5%0.02+15.2%+26.5%

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

Documents

Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.

ANTHEM

Anthem Biosciences IPO GMP Today with Trend

IPO Watch · 4 days ago

ANTHEM

Anthem Biosciences IPO Date, Price Band, Issue Size

IPO Watch · 4 days ago